<DOC>
	<DOCNO>NCT02728700</DOCNO>
	<brief_summary>This pilot phase I/II trial study side effect well sirolimus mycophenolate mofetil work prevent graft versus host disease ( GvHD ) patient hematologic malignancy undergo hematopoietic stem cell transplant ( HSCT ) . Biological therapy , sirolimus mycophenolate mofetil , use substance make live organism may stimulate suppress immune system different way stop tumor cell grow . Giving sirolimus mycophenolate mofetil hematopoietic stem cell transplant may better prevent graft-versus-host disease .</brief_summary>
	<brief_title>Sirolimus Mycophenolate Mofetil Preventing GVHD Patients With Hematologic Malignancies Undergoing HSCT</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Evaluate safety feasibility administer sirolimus mycophenolate mofetil ( MMF ) prophylaxis grade III-IV acute graft versus host disease ( aGvHD ) patient undergo mismatch unrelated related donor hematopoietic stem cell transplant ( HSCT ) . OUTLINE : Patients receive sirolimus orally ( PO ) start day -3 , 3 time week hospitalization week 6 month . Patients undergo HSCT day 0 . Patients also receive mycophenolate mofetil intravenously ( IV ) PO three time day ( TID ) day 1-180 . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow day 30 , 60 , 100 , 180 , 270 , 365 , yearly thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Subjects must one follow disease category : Acute myeloid leukemia ( AML ) beyond 2nd remission relapsed/refractory disease Acute lymphoblastic leukemia ( ALL ) beyond 2nd remission relapsed/refractory disease Chronic myeloid leukemia ( CML ) beyond 2nd chronic phase blast crisis Myelodysplastic syndrome ( MDS ) Myeloproliferative disorder include myeloid metaplasia myelofibrosis High risk nonHodgkin 's lymphoma ( NHL ) first remission Relapsed refractory NHL Hodgkin 's lymphoma ( HL ) beyond first remission Performance status Karnofsky &gt; = 70 % Lansky &gt; 70 % patient &lt; 16 year age Human leukocyte antigen ( HLA ) mismatch related unrelated donor identify 8/10 9/10 Willingness take oral medication transplantation period Willingness ability sign write informed consent ( assent applicable ) Prior myeloablative allogeneic autologous HSCT Human immunodeficiency virus ( HIV ) infection Pregnant lactating female Evidence uncontrolled active infection Down syndrome Serum creatinine ( CR ) &lt; 1.5mg/dl 24 hour CR clearance &lt; 50 ml/min Direct bilirubin &gt; 2 x upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2 x ULN Carbon monoxide diffuse capability test ( DLCO ) &gt; 60 % predicted child room air oxygen saturation &gt; 92 % Left ventricular ejection fraction &lt; 45 % childrenshortening fraction &lt; 26 % Fasting cholesterol &gt; 300 mg/dl triglyceride &gt; 300 lipid lower agent Patients receive investigational drug within 30 day enrollment study Patients prior malignancy except basal cell carcinoma treat carcinoma insitu ; cancer treat curative intent &gt; 5 year allow ; cancer treatment curative intent = &lt; 5 year allow</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>